RECRUITING Not applicable ClinicalTrials.gov

FIBERGRAFT Aeridyan Posterolateral Fusion Study

Sponsor: DePuy Synthes Products, Inc. • ClinicalTrials.gov ID: NCT07059065

Registry updated: 2026-09-25

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a post-market, prospective, controlled, multicenter clinical study to evaluate radiographic fusion and clinical outcomes of FIBERGRAFT™ Aeridyan Matrix bone graft substitute in subjects who undergo a 1-3 level instrumented lumbar posterolateral fusion surgery. This clinical study will be conducted at up to 10 clinical sites within the United States.

Interventions

FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute (Device)
FIBERGRAFT™ Aeridyan Matrix is a next generation synthetic bone graft that is resorbable, bioactive, and osteoconductive. FIBERGRAFT Aeridyan Matrix is composed of ultra-porous 45S5 bioactive glass granules, boron-based bioactive glass microspheres, and bovine type 1 collagen. The granules are made entirely of 45S5 bioactive glass fibers and feature a porous outer shell encasing an intricate nest of micro- and nano- fibers and microspheres. The nonporous microspheres are made entirely of boron-based bioactive glass and feature essential metallic ions such as zinc, copper, magnesium, and potassium. The highly biocompatible type 1 collagen5 serves as a carrier for the bioactive glass components. FIBERGRAFT Aeridyan Matrix is designed to have an adequate structural integrity for its application as a bone graft substitute material, while optimizing radiopacity and resorption.
Demineralized Bone Matrix (Device)
Demineralized Bone Matrix is to be used with bone marrow aspirate and mixed with autograft bone in accordance with approved indications per the IFU

Eligibility criteria

INCLUSION CRITERIA 1. Subjects who require a 1-3 level instrumented PLF fusion in the lumbar spine in conjunction with a 1 to 2 consecutive level posterior lumbar interbody fusion procedure between L1-S1. 2. Skeletally mature subjects at least 18 years of age at the time of consenting. 3. Willing to provide voluntary written informed consent prior to participation in the clinical study. EXCLUSION CRITERIA 1. Subjects who had previous fusion surgery at the index level(s). 2. Requiring a Posterolateral Fusion in the lumbar spine at more than three levels and/or an interbody fusion at more than two levels 3. Subjects who have demonstrated allergy or foreign body sensitivity to the implant or graft material. 4. Pregnant subjects or planning to become pregnant within the next 24 months. 5. Subjects diagnosed with severe osteoporosis which may prevent adequate fixation and thus preclude the use of these or any other orthopedic implant. 6. Subjects diagnosed with severe instabilities, vertebral fractures, spinal tumors. 7. Subjects who have an uncontrolled systemic or metabolic disease which, in the Investigator's opinion, would compromise their health, safety, or ability to participate or follow-up in this clinical study. 8. Subjects requiring use of an implantable bone graft stimulator or external bone graft stimulator. 9. Subjects that have infection or osteomyelitis at the graft site. Any medical or surgical condition that precludes the potential benefit of spinal surgery, in the opinion of the Investigator. 10. Any medical or surgical condition that precludes the potential benefit of spinal surgery, in the opinion of the Investigator. 11. Dependency on pharmaceutical drugs, drug abuse, or alcoholism resulting in a lack of subject cooperation. 12. Subjects unable to comply, and/or in the Investigator's opinion unable to comply, with the requirements of participation in the clinical study. 13. Enhanced Demineralized Bone Matrix product for the grafting control used within the posterolateral spine 14. Use of Bone Morphogenetic Protein (BMP) grafting material within the interbody cage(s). 15. Body Mass Index (BMI) ≥ 45 16. Unilateral posterior instrumentation 17. Subject is currently involved in a workers' compensation claim. 18. Subject has participated in an interventional clinical trial within the last 6 months or plans to participate in an interventional clinical trial within the next 24 months.

Conditions

Degenerative Spine Disease

Locations

UC Davis Health System — Sacramento, California, United States
University Of Illinois — Chicago, Illinois, United States
University of Kentucky Medical Center — Lexington, Kentucky, United States
Brigham And Women's Hospital — Boston, Massachusetts, United States
Rothman Orthopaedics Institute — Philadelphia, Pennsylvania, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment